Subject(s)
Angioedema/chemically induced , Antibodies, Monoclonal/adverse effects , Antibodies, Neutralizing/blood , Multiple Sclerosis, Relapsing-Remitting/therapy , Adult , Angioedema/blood , Angioedema/drug therapy , Antibodies, Monoclonal, Humanized , Female , Histamine Antagonists/therapeutic use , Humans , Multiple Sclerosis, Relapsing-Remitting/blood , Natalizumab , Treatment OutcomeABSTRACT
BACKGROUND: The efficacy of standardized Juniperus ashei extract was assessed in patients with allergic rhinoconjunctivitis due to European cypress pollens. METHODS: Forty adults with European cypress-allergic rhinoconjunctivitis were randomized to receive immunotherapy or a matched placebo. Specific immunotherapy was performed with a standardized, aluminum hydroxide-adsorbed J. ashei extract with a potency of 100 IR (arbitrary index of reactivity) containing 54 microg of Jun a 1/ml (Alustal, Stallergenes, France). Subcutaneous injections started in October 2000. The maintenance dose was 0.30 ml of the 100-IR concentration per month. Rhinitis and conjunctivitis symptoms were rated according to a 4-point score. RESULTS: Seventeen patients from the treated group and 15 patients from the placebo group completed year 2001; 14 in each group completed year 2002. A statistically significant improvement (41%, p < 0.02) in the conjunctivitis symptom score was observed in actively treated patients compared to the placebo group at the peak of the 2001 pollen season. Improvement in rhinitis (17%) was not significant. This significant improvement was greater at the peak of the 2002 pollen season (63%, p < 0.01). CONCLUSIONS: This study therefore indirectly validates the concept of treatment by major allergen because J. ashei is absent from the region in which this study was conducted.
Subject(s)
Conjunctivitis, Allergic/prevention & control , Cupressus/immunology , Immunization , Juniperus/immunology , Rhinitis, Allergic, Seasonal/prevention & control , Adsorption , Adult , Aged , Aluminum Hydroxide , Conjunctivitis, Allergic/immunology , Double-Blind Method , Female , Humans , Immunoglobulin E/blood , Immunoglobulin G/blood , Male , Middle Aged , Plant Extracts/immunology , Plant Extracts/therapeutic use , Pollen/immunology , Rhinitis, Allergic, Seasonal/immunology , Treatment OutcomeABSTRACT
The untranslated regions of mRNAs encoding heat-shock proteins have been reported to contain elements important to the post-transcriptional regulation of these key components of the stress response. In this report we describe an element from the 5'UTR of human Hsp70 mRNA that increases the efficiency of mRNA translation. Cloning of this region upstream of the coding sequence of two different reporter genes (firefly luciferase and chloramphenicol acetyltransferase) increases expression of the reporter under normal cell culture conditions by up to an order of magnitude. This effect was observed in three different promoter contexts (HSP, SV40 and CMV) and in six cell lines. The increase in protein production is not accompanied by any alteration in mRNA levels, suggesting that the element facilitates translation. 5' or 3' truncated sequences are ineffective in enhancing reporter expression, suggesting that the activity arises from the secondary structure of the element, rather than from some smaller defined motif. Computer analysis of this region revealed that it is able to form stable secondary structures (DeltaG approximately -292.6 kJ x mol(-1)). The Hsp70 element does not seem to act as an internal ribosome entry site. Incorporation of the sequence into plasmids used for DNA vaccination produces increased antibody responses, confirming that the sequence is functional in primary cells. These data suggest that the 5'UTR of human Hsp70 mRNA plays an important role in determining Hsp70 expression levels, and that it contains an element of general utility in enhancing recombinant protein expression systems.